The Business Research Company’s report on the Bleeding Disorders Treatment Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the bleeding disorders treatment market in recent years?
The increase in the number of diagnosed hemophilia patients is expected to propel the growth of the bleeding disorders treatment market going forward. Hemophilia is an inherited bleeding disorder where the blood does not clot properly. The treatment of Hemophilia entails replacement therapy, in which the missing or insufficient blood clotting factors are replaced with human plasma concentrates or recombinant (created from DNA) forms of clotting factors VIII or IX. For instance, according to the World Federation of Hemophilia (WFH), a Canada-based non-profit organization, as of 2022, there were 257,146 identified patients with hemophilia worldwide, including 208,957 with Hemophilia A and 42,203 with Hemophilia B. Therefore, the increasing number of diagnosed hemophilia patients is driving the growth of the bleeding disorders treatment market.
Access Your Free Sample of the Global Bleeding Disorders Treatment Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp
What is the projected market size of the bleeding disorders treatment industry, and how is it expected to grow?
The bleeding disorders treatment market size has grown strongly in recent years. It will grow from $16.95 billion in 2024 to $18.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased patient awareness, access to healthcare, advancements in hemophilia therapies, global market expansion.
The bleeding disorders treatment market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to aging population, personalized medicine, patient advocacy and support, rise in disposable income, rise in healthcare expenditure. Major trends in the forecast period include personalized treatment plans, expansion of telehealth services, advanced clotting factor therapies, rna-based treatments, access to orphan drug designation.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=7843&type=smp
Who are the key players driving competition in the bleeding disorders treatment market?
Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.
What key trends are expected to drive the bipolar disorder therapeutics market during the forecast period?
Major companies operating in the bleeding disorder treatment market are focusing on developing innovative technologies such as single-dose treatment to enhance treatment effectiveness and patient quality of life by minimizing the need for ongoing therapies. Single-dose treatment refers to a therapeutic approach that delivers a complete treatment in one administration, aiming for long-lasting effects without the need for multiple doses. For instance, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, launched BioMarin’s ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is specifically indicated for adults with severe hemophilia A (defined as FVIII activity levels below 1 IU/dL) who do not have pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) as determined by an FDA-approved test.
Which key geographies are driving the growth of the bleeding disorders treatment market?
North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report
What are the key segments driving growth in the bleeding disorders treatment market?
The bleeding disorders treatment market covered in this report is segmented –
1) By Treatment: Desmopressin (DDAVP), Hormone Replacement Therapy, Contraceptives, Anti-Fibrinolytic or Clot-Stabilizing Drugs, Fibrin Sealants, Drugs Applied To Cuts, Pipeline Analysis
2) By Disease Type: Hemophilia A, Hemophilia B, Von Willebrand disease, Liver disease, Other Disease Types
3) By End User: Hospitals, Clinics, Specialty Clinics, Research Institutes, Other End Users
Subsegments:
1) By Desmopressin (DDAVP): Intravenous Formulations, Nasal Spray Formulations
2) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy
3) By Contraceptives: Combined Oral Contraceptives, Progestin-Only Contraceptives
4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid, Aminocaproic Acid
5) By Fibrin Sealants: Tisseel, Artiss
6) By Drugs Applied To Cuts: Antiseptics, Topical Hemostatic Agents
7) By Pipeline Analysis: Upcoming Treatments in Development, Novel Therapeutics and Technologies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7843
How is the bleeding disorders treatment market defined, and what are its core characteristics?
Bleeding Disorders Treatment refers to medical therapies and interventions used to manage and control conditions that affect the blood’s ability to clot properly. These treatments aim to prevent excessive bleeding, manage symptoms, and improve quality of life.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
